Base de dados : MEDLINE
Pesquisa : C10.114.750.100 [Categoria DeCS]
Referências encontradas : 3427 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 343 ir para página                         

  1 / 3427 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449973
[Au] Autor:Sandhu SK; Hua W; MaCurdy TE; Franks RL; Avagyan A; Kelman J; Worrall CM; Ball R; Nguyen M
[Ad] Endereço:Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Electronic address: sukhminder.sandhu@fda.hhs.gov.
[Ti] Título:Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14.
[So] Source:Vaccine;35(22):2986-2992, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Guillain-Barré syndrome (GBS) is a serious acute demyelinating disease that causes weakness and paralysis. The Food and Drug Administration (FDA) began collaborating with the Centers for Medicare and Medicaid Services (CMS) to develop near real-time vaccine safety surveillance capabilities in 2006 and has been monitoring for the risk of GBS after influenza vaccination for every influenza season since 2008. METHODS: We present results from the 2010/11 to 2013/14 influenza seasons using the Updating Sequential Probability Ratio Test (USPRT), with an overall 1-sided α of 0.05 apportioned equally using a constant alpha-spending plan among 20 consecutive weekly tests, 5 ad hoc tests, and a 26th final end of season test. Observed signals were investigated using the self-controlled risk interval (SCRI) design. RESULTS: Over 15 million people were vaccinated in each influenza season. In the 2010/11 influenza season, we observed an elevated GBS risk during the season, with an end of season SCRI analysis finding a nonsignificant increased risk (RR=1.25, 95% CI: 0.96-1.63). A sensitivity analysis applying the positive predictive value of the ICD-9 code for GBS from the 2009/10 season estimated a RR=1.98 (95% CI: 1.42-2.76). Although the 2010/11 influenza vaccine suggested an increased GBS risk, surveillance of the identical vaccine in the 2011/12 influenza season did not find an increased GBS risk after vaccination. No signal was observed in the subsequent three influenza seasons. CONCLUSIONS: Conducting near real-time surveillance using USPRT has proven to be an excellent method for near real-time GBS surveillance after influenza vaccination, as demonstrated by our surveillance efforts during the 2010/11-2013/14 influenza seasons. In the 2010/2011 influenza season, in addition to the 2009 H1N1 influenza pandemic, using near real-time surveillance we were able to observe a signal early in the influenza season and the method has now become routine.
[Mh] Termos MeSH primário: Síndrome de Guillain-Barré/epidemiologia
Vacinas contra Influenza/efeitos adversos
Medicare
Vigilância da População/métodos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Centers for Medicare and Medicaid Services (U.S.)
Sistemas de Computação
Feminino
Síndrome de Guillain-Barré/etiologia
Seres Humanos
Vacinas contra Influenza/administração & dosagem
Masculino
Medição de Risco
Estados Unidos/epidemiologia
United States Food and Drug Administration
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Influenza Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779466
[Au] Autor:Dirlikov E; Kniss K; Major C; Thomas D; Virgen CA; Mayshack M; Asher J; Mier-Y-Teran-Romero L; Salinas JL; Pastula DM; Sharp TM; Sejvar J; Johansson MA; Rivera-Garcia B
[Ti] Título:Guillain-Barré Syndrome and Healthcare Needs during Zika Virus Transmission, Puerto Rico, 2016.
[So] Source:Emerg Infect Dis;23(1):134-136, 2017 01.
[Is] ISSN:1080-6059
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To assist with public health preparedness activities, we estimated the number of expected cases of Zika virus in Puerto Rico and associated healthcare needs. Estimated annual incidence is 3.2-5.1 times the baseline, and long-term care needs are predicted to be 3-5 times greater than in years with no Zika virus.
[Mh] Termos MeSH primário: Surtos de Doenças
Síndrome de Guillain-Barré/epidemiologia
Necessidades e Demandas de Serviços de Saúde/estatística & dados numéricos
Modelos Estatísticos
Infecção pelo Zika virus/epidemiologia
[Mh] Termos MeSH secundário: Previsões
Síndrome de Guillain-Barré/complicações
Síndrome de Guillain-Barré/terapia
Síndrome de Guillain-Barré/virologia
Seres Humanos
Incidência
Assistência de Longa Duração/estatística & dados numéricos
Método de Monte Carlo
Vigilância da População
Porto Rico/epidemiologia
Zika virus/patogenicidade
Zika virus/fisiologia
Infecção pelo Zika virus/complicações
Infecção pelo Zika virus/terapia
Infecção pelo Zika virus/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.3201/eid2301.161290


  3 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776345
[Au] Autor:Mateos-Hernández L; Villar M; Doncel-Pérez E; Trevisan-Herraz M; García-Forcada Á; Ganuza FR; Vázquez J; de la Fuente J
[Ad] Endereço:SaBio. Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ronda de Toledo s/n, 13005 Ciudad Real, Spain.
[Ti] Título:Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barré syndrome.
[So] Source:Oncotarget;7(46):74582-74591, 2016 11 15.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Guillain-Barré syndrome (GBS) is an autoimmune-mediated peripheral neuropathy of unknown cause. However, about a quarter of GBS patients have suffered a recent bacterial or viral infection, and axonal forms of the disease are especially common in these patients. Proteomics is a good methodological approach for the discovery of disease biomarkers. Until recently, most proteomics studies of GBS and other neurodegenerative diseases have focused on the analysis of the cerebrospinal fluid (CSF). However, serum represents an attractive alternative to CSF because it is easier to sample and has potential for biomarker discovery. The goal of this research was the identification of serum biomarkers associated with recovery from GBS. To address this objective, a quantitative proteomics approach was used to characterize differences in the serum proteome between a GBS patient and her healthy identical twin in order to lessen variations due to differences in genetic background, and with additional serum samples collected from unrelated GBS (N = 3) and Spinal Cord Injury (SCI) (N = 3) patients with similar medications. Proteomics results were then validated by ELISA using sera from additional GBS patients (N = 5) and healthy individuals (N = 3). All GBS and SCI patients were recovering from the acute phase of the disease. The results showed that Piccolo, a protein that is essential in the maintenance of active zone structure, constitutes a potential serological correlate of recovery from GBS. These results provided the first evidence for the Piccolo´s putative role in GBS, suggesting a candidate target for developing a serological marker of disease recovery.
[Mh] Termos MeSH primário: Biomarcadores
Proteínas do Citoesqueleto/sangue
Síndrome de Guillain-Barré/metabolismo
Síndrome de Guillain-Barré/reabilitação
Neuropeptídeos/sangue
Proteômica
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Proteínas Sanguíneas
Estudos de Casos e Controles
Feminino
Seres Humanos
Masculino
Meia-Idade
Modelos Biológicos
Proteoma
Proteômica/métodos
Recuperação de Função Fisiológica
Reprodutibilidade dos Testes
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Blood Proteins); 0 (Cytoskeletal Proteins); 0 (Neuropeptides); 0 (PCLO protein, human); 0 (Proteome)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.12789


  4 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452849
[Au] Autor:Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
[Ad] Endereço:*Vanderbilt University School of Medicine †Department of Surgery ‡Division of Surgical Oncology, Vanderbilt University Medical Center, Nashville, TN.
[Ti] Título:Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
[So] Source:J Immunother;40(5):196-199, 2017 Jun.
[Is] ISSN:1537-4513
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Immune-related adverse events are common and well-documented in patients treated with ipilimumab, a cytotoxic T-lymphocyte antigen-4 monoclonal antibody approved for the treatment of metastatic and stage III melanoma. Neurological complications are rare, but widely variable and potentially devastating. Here, we discuss a case of a patient who was treated with a single dose of ipilimumab for resected stage III melanoma. She subsequently developed pandysautonomia that manifested as a tonically dilated pupil, gastrointestinal dysmotility, urinary retention, and profound orthostatic hypotension. Guillain-Barré syndrome was diagnosed on electromyography. She was treated with intravenous immunoglobulin, droxidopa, and supportive care, with prolonged but eventual recovery. Given the broadening use of ipilimumab in the treatment of advanced and metastatic melanoma, awareness and recognition of its profound immune-mediated adverse effects are essential.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico
Síndrome de Guillain-Barré/diagnóstico
Imunoterapia/métodos
Ipilimumab/uso terapêutico
Melanoma/diagnóstico
Disautonomias Primárias/diagnóstico
Neoplasias Cutâneas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/efeitos adversos
Antígeno CTLA-4/imunologia
Transtornos de Deglutição
Feminino
Síndrome de Guillain-Barré/complicações
Síndrome de Guillain-Barré/terapia
Seres Humanos
Imunoterapia/efeitos adversos
Ipilimumab/efeitos adversos
Melanoma/complicações
Melanoma/terapia
Disautonomias Primárias/etiologia
Neoplasias Cutâneas/complicações
Neoplasias Cutâneas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (Ipilimumab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1097/CJI.0000000000000167


  5 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461111
[Au] Autor:Kahlmann V; Roodbol J; van Leeuwen N; Ramakers CRB; van Pelt D; Neuteboom RF; Catsman-Berrevoets CE; de Wit MCY; Jacobs BC
[Ad] Endereço:Department of Neurology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, The Netherlands; Department of Paediatric Neurology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, The Netherlands. Electronic address: vivienne.kahlmann@gmail.com.
[Ti] Título:Validated age-specific reference values for CSF total protein levels in children.
[So] Source:Eur J Paediatr Neurol;21(4):654-660, 2017 Jul.
[Is] ISSN:1532-2130
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To define age-specific reference values for cerebrospinal fluid (CSF) total protein levels for children and validate these values in children with Guillain-Barré syndrome (GBS), acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS). METHODS: Reference values for CSF total protein levels were determined in an extensive cohort of diagnostic samples from children (<18 year) evaluated at Erasmus Medical Center/Sophia Children's Hospital. These reference values were confirmed in children diagnosed with disorders unrelated to raised CSF total protein level and validated in children with GBS, ADEM and MS. RESULTS: The test results of 6145 diagnostic CSF samples from 3623 children were used to define reference values. The reference values based on the upper limit of the 95% CI (i.e. upper limit of normal) were for 6 months-2 years 0.25 g/L, 2-6 years 0.25 g/L, 6-12 years 0.28 g/L, 12-18 years 0.34 g/L. These reference values were confirmed in a subgroup of 378 children diagnosed with disorders that are not typically associated with increased CSF total protein. In addition, the CSF total protein levels in these children in the first 6 months after birth were highly variable (median 0.47 g/L, IQR 0.26-0.65). According to these new reference values, CSF total protein level was elevated in 85% of children with GBS, 66% with ADEM and 23% with MS. CONCLUSION: More accurate age-specific reference values for CSF total protein levels in children were determined. These new reference values are more sensitive than currently used values for diagnosing GBS and ADEM in children.
[Mh] Termos MeSH primário: Líquido Cefalorraquidiano/química
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Estudos de Coortes
Encefalomielite Aguda Disseminada/líquido cefalorraquidiano
Feminino
Síndrome de Guillain-Barré/líquido cefalorraquidiano
Seres Humanos
Masculino
Valores de Referência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  6 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200423
[Au] Autor:Tang X; Zhao S; Chiu APY; Wang X; Yang L; He D
[Ad] Endereço:Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
[Ti] Título:Analysing increasing trends of Guillain-Barré Syndrome (GBS) and dengue cases in Hong Kong using meteorological data.
[So] Source:PLoS One;12(12):e0187830, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Guillain-Barré Syndrome (GBS) is a severe paralytic neuropathy associated with virus infections such as Zika virus and Chikungunya virus. There were also case reports of dengue fever preceding GBS. With the aim to understand the mechanisms of GBS and dengue outbreaks, this ecological study investigates the relationships between GBS, dengue, meteorological factors in Hong Kong and global climatic factors from January 2000 to June 2016. METHODS: The correlations between GBS, dengue, Multivariate El Niño Southern Oscillation Index (MEI) and local meteorological data were explored by Spearman's Rank correlations and cross-correlations. Three Poisson regression models were fitted to identify non-linear associations among GBS, dengue and MEI. Cross wavelet analyses were applied to infer potential non-stationary oscillating associations among GBS, dengue and MEI. FINDINGS AND CONCLUSION: We report a substantial increasing of local GBS and dengue cases (mainly imported) in recent year in Hong Kong. The seasonalities of GBS and dengue are different, in particular, GBS is low while dengue is high in the summer. We found weak but significant correlations between GBS and local meteorological factors. MEI could explain over 17% of dengue's variations based on Poisson regression analyses. We report a possible non-stationary oscillating association between dengue fever and GBS cases in Hong Kong. This study has led to an improved understanding about the timing and ecological relationships between MEI, GBS and dengue.
[Mh] Termos MeSH primário: Temperatura Baixa/efeitos adversos
Dengue/epidemiologia
Surtos de Doenças
El Niño Oscilação Sul
Síndrome de Guillain-Barré/epidemiologia
[Mh] Termos MeSH secundário: Vírus Chikungunya/isolamento & purificação
Dengue/complicações
Vírus da Dengue/isolamento & purificação
Síndrome de Guillain-Barré/virologia
Hong Kong/epidemiologia
Seres Humanos
Estações do Ano
Luz Solar
Zika virus/isolamento & purificação
Infecção pelo Zika virus/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171229
[Lr] Data última revisão:
171229
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0187830


  7 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245299
[Au] Autor:Zhang N; Cao J; Zhao M; Sun L
[Ad] Endereço:aDepartment of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, JilinbDepartment of Neurology, Yidu Central Hospital, Weifang, Shandong, China.
[Ti] Título:The introspection on the diagnosis and treatment process of a case of Guillain-Barré syndrome (GBS) attributed to systemic lupus erythematosus (SLE): A case report.
[So] Source:Medicine (Baltimore);96(49):e9037, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Systemic lupus erythematosus (SLE) is an autoimmune inflammatory connective tissue disorder. It may cause neurologic damage which is mainly characterized by central and mental system, while peripheral sexual damage is relatively rare in which Guillain-Barré Syndrome (GBS) as the first performance is more rare . GBS is an autoimmune peripheral neuropathy usually triggered by an antecedent bacterial or viral infection, with SLE being a rare cause. PATIENT CONCERNS: A 65-year-old male presented to the hospital with progressive numbness and adynamia in extremities. His vital signs were stable. 5 days later, his condition aggravated and mechanical ventilation was necessitated owing to severe dyspnea. DIAGNOSES: Based on the clinical symptoms and results of the lumbar puncture and electromyography, he was first diagnosed as GBS, however, after treatment his condition was deteriorate and the blood test showed abnormal immune indices, then renal biopsy was performed, which confirmed the diagnosis of peripheral nervous system in patients with systemic lupus erythematosus (PNS-SLE). INTERVENTIONS: Firstly he was treated with intravenous immunoglobulin (IVIG) for 5 days. After his condition deterioration, he was conducted endotracheal intubation and, finally, a tracheostomy was performed. Later on he was treated with steroid therapy for several weeks. OUTCOMES: The patient showed remarkable recovery and was able to walk on his own by the time of discharge. LESSONS: PNS-SLE can, by itself, be one of the main causes of morbidity and mortality. Electromyography and renal biopsy should be considered when relevant. Peripheral neuropathy in SLE should be given greater recognition, and rarer forms of presentation should be taken seriously in the differential diagnosis when the clinical picture is atypical. Glucocorticoids may play an important role in the treatment of PNS-SLE.
[Mh] Termos MeSH primário: Síndrome de Guillain-Barré/diagnóstico
Imunoglobulinas Intravenosas/uso terapêutico
Lúpus Eritematoso Sistêmico/complicações
[Mh] Termos MeSH secundário: Idoso
Diagnóstico Diferencial
Eletromiografia
Glucocorticoides/uso terapêutico
Síndrome de Guillain-Barré/tratamento farmacológico
Síndrome de Guillain-Barré/etiologia
Seres Humanos
Masculino
Doenças do Sistema Nervoso Periférico/diagnóstico
Doenças do Sistema Nervoso Periférico/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009037


  8 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232807
[Au] Autor:Qi B; Meng C
[Ad] Endereço:Department of Graduate School, Jining Medical University, Jining, Shandong Province, China; Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China.
[Ti] Título:Retrospective Analysis and Comment on the Time Interval Between Surgery and Onset of Guillain-Barré Syndrome.
[So] Source:World Neurosurg;109:499, 2018 01.
[Is] ISSN:1878-8769
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome de Guillain-Barré
[Mh] Termos MeSH secundário: Seres Humanos
Estudos Retrospectivos
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  9 / 3427 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28471623
[Au] Autor:Tomljenovic L
[Ad] Endereço:Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Guillian-Barré Syndrome and Acute Disseminated Encephalomyelitis related to the Bivalent Oral Poliovirus Vaccine.
[So] Source:Isr Med Assoc J;18(10):619-622, 2016 Oct.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Mh] Termos MeSH primário: Encefalomielite Aguda Disseminada/etiologia
Síndrome de Guillain-Barré/etiologia
Vacina Antipólio Oral/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Encefalomielite Aguda Disseminada/imunologia
Síndrome de Guillain-Barré/imunologia
Seres Humanos
Vacina Antipólio Oral/efeitos adversos
Vacina Antipólio Oral/imunologia
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  10 / 3427 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28471617
[Au] Autor:Tasher D; Kopel E; Anis E; Grossman Z; Somekh E
[Ad] Endereço:Pediatric Infectious Diseases Unit, Wolfson Medical Center, Holon, Israel.
[Ti] Título:Causality Assessment of Serious Neurologic Adverse Events Following bOPV National Vaccination Campaign in Israel.
[So] Source:Isr Med Assoc J;18(10):590-593, 2016 Oct.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: During 2013-2014 Israel experienced a continuous circulation of wild poliovirus type 1 (WPV1) but with no clinical cases. WPV1 circulation was gradually terminated following a national vaccination campaign of bivalent oral poliovirus vaccine (bOPV) for 943,587 children < 10 years. Four cases of children with neurological manifestations that appeared following bOPV vaccinations were reported during the campaign: three of Guillain-Barré syndrome (GBS) and one of acute disseminated encephalomyelitis (ADEM). OBJECTIVES: To present an analysis of these cases, the rapid response and the transparent publication of the results of this analysis. METHODS: The clinical, laboratory and epidemiological data of these four patients were available during the analysis. In addition, data regarding the incidence of GBS and ADEM during previous years, and reported cases of acute flaccid paralysis (AFP) and the incidence of Campylobacter jejuni enteritis were collected from the Epidemiology Department of the Israel Ministry of Health. RESULTS: The incidence of GBS among bOPV-vaccinated children was not higher than among bOPV-unvaccinated children. For all the cases reviewed the "incubation period" from vaccination to the event was longer than expected and other more plausible causes for the neurologic manifestations were found. There is no evidence in the literature of a causal relationship between bOPV and ADEM. CONCLUSIONS: There was no association between the bOPV vaccine and the reported neurological manifestations. We believe that our experience may assist other public health professionals when confronting a similar problem of alleged side effects during a mass medical intervention.
[Mh] Termos MeSH primário: Encefalomielite Aguda Disseminada/etiologia
Síndrome de Guillain-Barré/etiologia
Vacina Antipólio Oral/administração & dosagem
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Encefalomielite Aguda Disseminada/epidemiologia
Síndrome de Guillain-Barré/epidemiologia
Seres Humanos
Programas de Imunização
Incidência
Lactente
Israel/epidemiologia
Poliomielite/prevenção & controle
Poliovirus/isolamento & purificação
Vacina Antipólio Oral/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE



página 1 de 343 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde